Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD
-
Upload
ovarian-cancer-national-alliance -
Category
Health & Medicine
-
view
68 -
download
1
Transcript of Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD
![Page 1: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/1.jpg)
Beth Y. Karlan, M.D. Director, Women’s Cancer Program and Division of Gynecologic Oncology, Cedars-Sinai Medical Center
Ovarian Cancer National Alliance Annual Conference 2015, San Diego, CA
Genomics in Risk Assessment and Tailoring Treatment for Women with Ovarian Cancer
Ovarian Cancer Update 2015
![Page 2: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/2.jpg)
Precision Cancer Medicine
• Has captured the imagination and hopes of patients, physicians, scientists, and industry
• Treatments custom-tailored to patients’ and tumors’ genetic makeup to improve survival
• Would avoid “wasted time” on ineffective strategies and also reduce toxicity
• Successes to date have been exhilarating but approach still not standard for most
![Page 3: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/3.jpg)
State of the Union Address 2015
![Page 4: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/4.jpg)
Precision Medicine Initiative Includes plan to collect genetic data on one million Americans so scientists can develop drugs and treatments tailored to the individual characteristics of individual patients.
$215 million Budget Request Includes: $130 million for research consortium $70 million for the NCI $10 million for the FDA $5 million for health information technology
![Page 5: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/5.jpg)
• Goes beyond single gene test approach
• Multiplex sequencing is becoming affordable and available in a clinically relevant timeframe
• Can be done on tumor biopsy tissue or even “liquid biopsy” with CTCs or cfDNA
• Opening the door to new era of clinical cancer genomics
Corless; Science, 2011
Precision Cancer Medicine
![Page 6: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/6.jpg)
Precision Medicine has Already Transformed the Therapeutic Approach to Lung Cancer
Traditionally lung cancer was treated according to histology A growing list of genetic alterations have helped define subgroups Molecular therapeutics to target these mutations have
demonstrated improved responses in clinical trials Companion diagnostics have been developed to match molecular
target and treatment Lung Cancer outcomes have been improved by this individualized approach to therapy
![Page 7: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/7.jpg)
Survival of patients with an oncogenic driver mutations who received targeted therapy was >1 yr longer compared to those without a driver mutation or targeted rx
2014
![Page 8: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/8.jpg)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 2 4 6 8 10
Pro
po
rtio
n S
urv
ivin
g
Years After Diagnosis
1973-79
1980-89
1990-97
Progress Towards Improving Ovarian Cancer Survival Has Been Insufficient
![Page 9: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/9.jpg)
Progress Towards Improving Ovarian Cancer Survival Has Been Insufficient
![Page 10: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/10.jpg)
Multiple Strategies are needed to Reduce the Number of Women Dying
from Ovarian Cancer • Improved therapeutic approaches:
Scientifically-informed clinical trials accounting for tumor subtypes and molecular pathogenesis
Targeted agents and immunotherapies
Timing and Approach to Optimizing Cytoreductive Surgical Outcomes
• Professional and Public Education
• Early detection and Prevention
![Page 11: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/11.jpg)
Multiple Strategies are needed to Reduce the Number of Women Dying
from Ovarian Cancer • Improved therapeutic approaches:
• Scientifically-informed clinical trials accounting for tumor subtypes and molecular pathogenesis
• Targeted agents and immunotherapies
• Timing and Approach to Optimizing Cytoreductive Surgical Outcomes
• Professional and Public Education
• Early detection and Prevention
![Page 12: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/12.jpg)
Survival Correlates with Adherence to NCCN Guidelines
Stage III/IV
Women live twice as long when care is in accordance with standard guidelines (20 mos vs. 40 mos)
Bristow RE, et al: JNCI 105:825, 2013
![Page 13: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/13.jpg)
Gynecologic Cancer Education and Awareness Act: Johanna’s Law, signed in 2007
![Page 14: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/14.jpg)
Testimony Before the United States House of Representatives:
Gynecologic Cancer Education and Awareness Act Johanna’s Law
![Page 15: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/15.jpg)
Multiple Strategies are needed to Reduce the Number of Women Dying
from Ovarian Cancer • Professional and Public Education
• Improved therapeutic approaches:
• Scientifically-informed clinical trials accounting for tumor subtypes and molecular pathogenesis
• Targeted agents and immunotherapies
• Timing and Approach to Optimizing Cytoreductive Surgical Outcomes
• Early detection and Prevention
![Page 16: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/16.jpg)
Early Detection Would have a Greater Impact on Ovarian Cancer Survival than a
New Therapy for Advanced Disease
![Page 17: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/17.jpg)
Early Detection Would have a Greater Impact on Ovarian Cancer Survival than a
New Therapy for Advanced Disease
![Page 18: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/18.jpg)
Stage at diagnosis
5 Year Survival
Early detection alone, with current day therapies, could increase overall survival by over 100%
Most ovarian cancers are detected after they have already spread beyond the ovary and the 5 yr survival is < 30%
I II III IV 0
25
50
75
100
0
25
50
75
100
I II III IV
Thousands of Lives Could be Saved by Early Detection but an Effective Test Remains Elusive
![Page 19: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/19.jpg)
Ovarian Cancer Screening in Asymptomatic Healthy Women (at average risk) is NOT Effective
![Page 20: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/20.jpg)
WOMEN > 55 - 74 years
STUDY GROUP 34,253 eligible women 212 primary invasive
ovarian/tubal/peritoneal cancers 118 deaths
CONTROL GROUP 34,304 eligible women 176 ovarian/tubal/peritoneal cancers
100 deaths
• Annual screening with TVS and CA125 • Median follow up 12.4 years (10.9 -13) • No reduction in Ovarian Cancer Mortality
(odds ratio 1.18; 95%CI 0.91-1.54) • 15% (163/1080) of patients who had ‘false
positives’ went to surgery and had major complications
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
Buys, et al. JAMA 2011
![Page 21: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/21.jpg)
• Ovarian cancer screening cannot be recommended
in the general population
• Screening using TVU and serum CA125 was
harmful to some
• This does not mean screening for ovarian cancer is
not possible, but this strategy will not save lives.
• We need to focus our efforts on understanding the
origin and natural history of ovarian cancer and
individualize risk groups to maximize the use of
screening resources
PLCO: Implications for Clinical Practice
Buys, et al. JAMA 2011
![Page 22: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/22.jpg)
UK Collaborative Trial of Ovarian Cancer Screening (UKTOCS) Trial
200,000 >50 years & post-
menopause
MULTIMODAL SCREEN GROUP
CA 125 50,000
CONTROL GROUP 100,000
ULTRASOUND GROUP
TV Ultrasound 50,000
OBJECTIVES
Primary: Ovarian Cancer Mortality
Secondary: Morbidity
Health Economics Quality of Life Acceptability Compliance
Additional: Serum Bank
Ian Jacobs, Usha Menon, et al
![Page 23: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/23.jpg)
UKCTOCS Multimodal Protocol
USS
Annual CA 125
ROC Algorithm
SURGERY
ABNORMAL
INTERMED
NORMAL
Repeat CA 125
Ian Jacobs, Usha Menon, et al
![Page 24: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/24.jpg)
Multimodality Strategy (MMS) Arm 46,237 women >50 yo
(296,911 woman-yrs of annual screens)
640 surgeries, 133 primary invasive EOCs
Sensitivity 85.8% (95% CI, 79.3%-90.9%)
Specificity 99.8% (95% CI, 99.8%-99.8%)
4.8 surgeries/invasive EOC Detected
ROCA alone detected 87.1% invasive EOCs
** Nearly double the performance of fixed cut off CA125s
May 2015
![Page 25: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/25.jpg)
CA125 used as a “Dynamic Biomarker” Finds
More Early Cancers
No mortality data yet, but disease “downstaging” seen as a
result of MMS screening intervention:
• 41.4% invasive EOC were Stage 1 or 2 disease
• 82% were type II HGSC
Menon U, et al JCO 2015
![Page 26: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/26.jpg)
Perhaps we need to rethink our approach…
• Early detection trials have not YET
been able to reduce mortality
• Many candidate biomarkers have
been identified but none have
performed well enough to apply to screening
• Thus far, imaging has underperformed and remains expensive
• Recent evidence points to precursor lesion in fallopian tube for high grade serous cancers
• Primary prevention may be a better strategy than early detection for the majority ovarian cancers
![Page 27: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/27.jpg)
EOC Subtypes and Unique Characteristics
Bookman, et al. JNCI, 2014
![Page 28: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/28.jpg)
Recent Findings Point to the Fallopian Tube as the Origin of Most HGSC
• Occult cancers found at prophylactic surgeries on BRCAmut carriers are usually seen in the fimbria of the fallopian tube
• In ovarian cancer cases, the fallopian tubes frequently contain serous tubal intraepithelial carcinoma (STIC) precursor lesions
• Virtually all STICs contain TP53 mutations identical to those seen in almost all HGSC
• Most high grade serous ovarian cancers originate in the fallopian tube
![Page 29: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/29.jpg)
Ear
Secretory Cell Transformation and Tumor Progression in the Fallopian Tube Fimbria Results in HGSC and Peritoneal Metastasis
Ronny Drapkin, with permission
![Page 30: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/30.jpg)
Author Number Tumor (%) Tubal Involvement (%)
Colgan (2001) 39 5 (13) 4 (80)
Leeper (2002) 30 5 (17) 3 (60)
Powell (2005) 67 7 (10) 4 (57)
Carcangiu (2006) 50 6 (12) 4 (67)
Finch (2006) 159 7 (4) 6 (86)
Callahan (2007) 100 7 (7) 7 (100)
Hirst (2009) 45 4 (9) 4 (100)
TOTAL 490 41 (8) 32 (78)
Most Occult Cancers at RRSO in BRCAmut
Carriers are in the Fallopian Tubes
![Page 31: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/31.jpg)
Author Number Tumor (%) Tubal Involvement (%)
Colgan (2001) 39 5 (13) 4 (80)
Leeper (2002) 30 5 (17) 3 (60)
Powell (2005) 67 7 (10) 4 (57)
Carcangiu (2006) 50 6 (12) 4 (67)
Finch (2006) 159 7 (4) 6 (86)
Callahan (2007) 100 7 (7) 7 (100)
Hirst (2009) 45 4 (9) 4 (100)
TOTAL 490 41 (8) 32 (78)
Most Occult Cancers at RRSO in BRCAmut
Carriers are in the Fallopian Tubes
![Page 32: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/32.jpg)
Author Number Tumor (%) Tubal Involvement (%)
Colgan (2001) 39 5 (13) 4 (80)
Leeper (2002) 30 5 (17) 3 (60)
Powell (2005) 67 7 (10) 4 (57)
Carcangiu (2006) 50 6 (12) 4 (67)
Finch (2006) 159 7 (4) 6 (86)
Callahan (2007) 100 7 (7) 7 (100)
Hirst (2009) 45 4 (9) 4 (100)
TOTAL 490 41 (8) 32 (78)
Most Occult Cancers at RRSO in BRCAmut
Carriers are in the Fallopian Tubes
![Page 33: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/33.jpg)
Author Number Tumor (%) Tubal Involvement (%)
Colgan (2001) 39 5 (13) 4 (80)
Leeper (2002) 30 5 (17) 3 (60)
Powell (2005) 67 7 (10) 4 (57)
Carcangiu (2006) 50 6 (12) 4 (67)
Finch (2006) 159 7 (4) 6 (86)
Callahan (2007) 100 7 (7) 7 (100)
Hirst (2009) 45 4 (9) 4 (100)
TOTAL 490 41 (8) 32 (78)
Most Occult Cancers at RRSO in BRCAmut
Carriers are in the Fallopian Tubes
![Page 34: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/34.jpg)
Kim et al. PNAS, 2012
Animal Models Further Highlight the Tubal Origin of Serous “Ovarian Cancer”
Animals with conditional Dicer-Pten deletions develop ascites, fallopian tube tumors that spread to ovaries, and have extensive peritoneal metastasis resembling human disease.
Kaplan-Meier survival curve of control and DKO animals demonstrate lethality of lesion.
Tumor histology with papillary structures and nuclear polymorphism is characteristic of HGSC
![Page 35: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/35.jpg)
Kim et al. PNAS, 2012
Unilateral oophorectomy
Bilateral oophorectomy
Unilateral salpingectomy
Bilateral salpingectomy
Bilateral Salpingectomy Prevents Tumor Development, Metastasis and Death
Animal Models Further Highlight the Tubal Origin of Serous “Ovarian Cancer”
![Page 36: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/36.jpg)
Ovarian Cancer May be a Preventable Disease
Serous Tubal in situ Carcinoma (STIC)
Removing the ovaries doesn’t prevent ovarian cancer, but removing the fallopian tube does.
Seems to be an important lesson there!
![Page 37: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/37.jpg)
Salpingectomy significantly reduced ovarian cancer risk: HR 0.65 (95% CI=0.52-0.81) “Dose Response”: Bil-Salp twice as effective as Uni-Salp
HR 0.35 vs 0.71
>250,000 women who had surgery for benign indications and 5.5 million controls
![Page 38: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/38.jpg)
Salpingectomy significantly reduced ovarian cancer risk: HR 0.65 (95% CI=0.52-0.81) “Dose Response”: Bil-Salp twice as effective as Uni-Salp
HR 0.35 vs 0.71
>250,000 women who had surgery for benign indications and 5.5 million controls
CONCLUSION: Removal of fallopian tubes by itself is an effective measure to reduce ovarian cancer risk in the general population
![Page 39: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/39.jpg)
158 women undergoing TLH +/- BS-OR:
They assessed AMH, FSH, antral follicle count, ovarian size and blood flow (by TVS and Doppler)
April 2013
![Page 40: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/40.jpg)
158 women undergoing TLH +/- BS-OR:
They assessed AMH, FSH, antral follicle count, ovarian size and blood flow (by TVS and Doppler)—and found no difference
April 2013
![Page 41: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/41.jpg)
158 women undergoing TLH +/- BS-OR:
They assessed AMH, FSH, antral follicle count, ovarian size and blood flow (by TVS and Doppler)—and found no difference
No difference in OR time, p-op Hgb, hospital stay, or recovery
April 2013
![Page 42: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/42.jpg)
158 women undergoing TLH +/- BS-OR:
They assessed AMH, FSH, antral follicle count, ovarian size and blood flow (by TVS and Doppler)—and found no difference
No difference in OR time, p-op Hgb, hospital stay, or recovery
CONCLUSION: BS-OR appears safe and should be widely considered to prevent ovarian cancer
April 2013
![Page 43: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/43.jpg)
Pathologic Conditions that Could be Avoided with Routine Salpingectomy
![Page 44: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/44.jpg)
Routine Salpingectomy Should Be A New Standard of Care
![Page 45: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/45.jpg)
Routine Salpingectomy Should Be a New Standard of Care
• It’s safe and can prevent most ovarian cancers
• It can reduce rates of post-hysterectomy adnexal masses
• It should be performed:
– As a standard part of hysterectomy procedures
– In place of tubal ligation for sterilization
– At C-sections, if childbearing complete
![Page 46: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/46.jpg)
Multiple Strategies are needed to Reduce the Number of Women Dying
from Ovarian Cancer • Improved therapeutic approaches:
Timing and Approach to Optimizing Cytoreductive Surgical Outcomes
Targeted agents and immunotherapies
Scientifically-informed clinical trials accounting for tumor subtypes and molecular pathogenesis
• Professional and Public Education
• Early detection and Prevention
![Page 47: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/47.jpg)
Cytoreductive Surgery to NO visible disease has the greatest impact on Overall Survival
Dubois et al, Cancer, 2009
![Page 48: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/48.jpg)
Is it Surgical Effort or Tumor Biology that determines cytoreduction status?
We need a way to reliably predict no visible residual disease preoperatively to better inform our clinical decision making
![Page 49: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/49.jpg)
Individualize the Surgical Approach to Assess Likelihood of Optimal Cytroreduction
Women w/
suspected ovarian
cancer
Primary
Assessment
Ovarian
Cancer QI
Committee
Laparoscopy:
Validated score
R0 not
feasible
NACT
R0 feasible
Primary
TRS
Courtesy of A. Sood
Triage Laparoscopy
![Page 50: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/50.jpg)
Optimal
Interval
Cytoreduction
Molecular Predictor of Residual Disease Could Help Direct Treatment and Improve Survival
Remission
Remission
Chemotherapy
Adjuvant RXs
Targeted +/-
Immuno- RXs
+
Tumor Signature
Or Serum Biomarkers
![Page 51: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/51.jpg)
Multiple Strategies are needed to Reduce the Number of Women Dying
from Ovarian Cancer • Improved therapeutic approaches:
Timing and Approach to Optimizing Cytoreductive Surgical Outcomes
Targeted agents and immunotherapies
Scientifically-informed clinical trials accounting for tumor subtypes and molecular pathogenesis
• Professional and Public Education
• Early detection and Prevention
![Page 52: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/52.jpg)
![Page 53: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/53.jpg)
Molecularly Targeted Agent with Companion Diagnostic now available for some Ovarian Cancers
![Page 54: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/54.jpg)
Cancer Immunotherapies Are Significantly Improving Treatment Responses and Survival
![Page 55: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/55.jpg)
There are Many Opportunities for Immune Modulation in Ovarian Cancer: Especially in Certain Subtypes
Zsiros, E, et al Current Opinon-Oncology
![Page 56: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/56.jpg)
Multiple Strategies are needed to Reduce the Number of Women Dying
from Ovarian Cancer • Improved therapeutic approaches:
Timing and Approach to Optimizing Cytoreductive Surgical Outcomes
Targeted agents and immunotherapies
Scientifically-informed clinical trials accounting for tumor subtypes and molecular pathogenesis
• Professional and Public Education
• Early detection and Prevention
![Page 57: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/57.jpg)
Ovarian Cancer is Many Diseases and Molecularly Complex
Vaughan S, et al.: Nature Reviews 2011
![Page 58: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/58.jpg)
EOC Subtypes and Unique Characteristics
Bookman, et al. JNCI, 2014
![Page 59: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/59.jpg)
Jamal-Hanjani, M, et al. CCR, 2015
Selection pressures such as chemotherapy or microenvironment factors such as hypoxia, infiltrating stromal and immune cells can contribute to therapeutic failure and resistance
Tumor Heterogeneity and Clonal Evolution
![Page 60: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/60.jpg)
Identifying Actionable Molecular Drivers at a Specific Point in Time Remains Challenging
• Establishing clonal dominance of a driver event from one biopsy is not trivial
• Need to determine stability of actionable alterations—both spatially and longitudinally through disease course in order to distinguish clonally dominant events
• Use of NGS for patient stratification and data interpretation will help determine drug-target interaction and response to therapy
• Need to keep in mind “inconsequential mutations” that accumulate over time, esp in hyper-mutant tumors. (Bioinformatic algorithms can help predict these somatic mutations)
![Page 61: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/61.jpg)
Cellular and Genomic Context of Mutations to Guide Treatment Decisions
Cellular context matters: Melanomas vs Colon cancers with BRAFv600E mutations
Clonal diversity: Small cell hypercalcemic ovarian cancer vs high grade serous ovarian cancer
Acquired resistance mutations: To drug target or activated downstream or parallel pathway
Identification of Driver vs Passenger mutations
Horlings, et al, JAMA Oncology, 2015
![Page 62: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/62.jpg)
Gerlinger M, et al.: NEJM 366:883; 2012
Tumor Heterogeneity Presents Significant
Challenge to Precision Cancer Medicine
Biopsies obtained from multiple tumor sites demonstrate marked molecular heterogeneity--with no two sites being identical.
![Page 63: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/63.jpg)
Adapting Clinical Trials to Address Cancer Heterogeneity
• Current trials begin to address inter-patient heterogeneity—but not dynamic tumor changes or the intra-tumor clonal heterogeneity
• Frequently based on only one biopsy site, despite recognition of clonal and subclonal frequencies
• Often uses archival tissue vs freshly procured biopsy
• How do we maximize therapeutic benefits of molecular profiling information?
• Need to harness realities of cost, access to sufficient tumor tissue DNA quality/quantity
![Page 64: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/64.jpg)
Tumor Biopsy
Sample Prep
Pathology Sequencing Analysis
Gene ALK BRAF EGFR ERBB2 PIK3CA PTEN
Status WT V600E WT WT WT WT
CLIA Pending
Sequence Results
Can this be done in a clinically relevant timeframe?
28 days
Tumor Biopsy to Sequencing Results
Roychowdhury S, et al.: Sci Transl Med; 2011
![Page 65: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/65.jpg)
>60% tumor Tumor Biopsy
Sequencing & Analysis
Buccal swab or
Blood (germline)
Target X
Target Y
Target Z
Discovery
Trial: X
Trial: Y
Trial: Z
Basic Research
Treatment Recommendations Based on Molecular
Analysis, Targetable Genes, and Available Agents
Roychowdhury S, et al.: Sci Transl Med; 2011
![Page 66: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/66.jpg)
Roychowdhury S, et al.: Sci Transl Med ; 2011
Treatment decisions now require a multidisciplinary discussion between clinicians, pathologists, geneticists, translational scientists and ethicists
A New Paradigm in Clinical Decision Making
![Page 67: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/67.jpg)
Precision Cancer Medicine Clinical Trials
• Umbrella Trials: One histology (stem) but evaluates multiple predictive biomarkers (spokes) to offer drug matching under one protocol (e.g. I-SPY2, ALCHEMIST trials)
• Basket Trials: Histology agnostic but tumors share a common molecular aberration are in the same basket and matched with a targeted drug (e.g. NCI-MATCH trial)
![Page 68: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/68.jpg)
NCI MATCH: Molecular Analysis for Therapy CHoice
![Page 69: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/69.jpg)
NCI MATCH: Molecular Analysis for Therapy CHoice
![Page 70: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/70.jpg)
![Page 71: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/71.jpg)
Novel Precision Medicine Clinical Trials are Needed in Ovarian Cancer
• Trials utilizing “one size fits all” approach have yielded disappointing results—we need to move beyond Plat-S and Plat-R criteria!
• Molecular subgroups can be defined but tumor heterogeneity and adaptive changes remain poorly understood and difficult to target
• We need better (non-invasive) ways to molecularly profile tumors at recurrence (such as core biopsy(s), CTC, cfDNA, molecular imaging, etc)
• Individualized treatments to match tumors trajectory and heterogeneity are needed
![Page 72: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/72.jpg)
Precision Cancer Medicine is Here to Stay
• Number of agents available to target molecular drivers is rapidly increasing
• Companion diagnositics enable matching of right agent to an individual patient/tumor
• Organ-agnostic clinical trials are in progress
• FDA Fast Track Designation Program was designed to get important new drugs to the patient faster
• Treatment algorithms based on molecular targets are already improving outcomes for some patients
BUT—”personalized medicine” is still a goal and not a reality for most patients. We need to advocate and fast track advances for ovarian cancer
![Page 73: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/73.jpg)
Call to Action
• Ovarian cancer is a disease in urgent need of more effective therapies and improved outcomes
• Effective prevention and early detection strategies will offer an avenue to reduced mortality
• Molecular signatures may allow us to better triage patients to surgery and point to scientifically- informed therapeutic strategies
• “One size fits all” approaches need to be abandoned
• New insights into the tumor microenvironment, immune modulation, microbiome influences, lifestyle, etc—will further add to therapeutic success
![Page 74: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/74.jpg)
Maintaining “Personable-ness” in Personalized Medicine: Doctoring Should Still Play a Role
![Page 75: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/75.jpg)
Women’s Cancer Program Cedars Sinai Medical Center
![Page 76: Mello Abrams Lecture: Ovarian Cancer Update: Beth Karlan, MD](https://reader033.fdocuments.us/reader033/viewer/2022042820/55d15454bb61eb23778b4695/html5/thumbnails/76.jpg)